Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up

BACKGROUND: Nivolumab plus ipilimumab (NIVO+IPI) demonstrated superior efficacy over sunitinib (SUN) for previously untreated advanced renal cell carcinoma (aRCC) in CheckMate 214, with a manageable safety profile. We report efficacy and safety with extended follow-up amongst Japanese patients. METH...

Descripción completa

Detalles Bibliográficos
Autores principales: Tomita, Yoshihiko, Kondo, Tsunenori, Kimura, Go, Inoue, Takamitsu, Wakumoto, Yoshiaki, Yao, Masahiro, Sugiyama, Takayuki, Oya, Mototsugu, Fujii, Yasuhisa, Obara, Wataru, Motzer, Robert J, Uemura, Hirotsugu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6978670/
https://www.ncbi.nlm.nih.gov/pubmed/31633185
http://dx.doi.org/10.1093/jjco/hyz132

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6978670/
https://www.ncbi.nlm.nih.gov/pubmed/31633185
http://dx.doi.org/10.1093/jjco/hyz132

Ejemplares similares